CN Stock MarketDetailed Quotes
002932 Wuhan Easy Diagnosis Biomedicine
- 16.12
- -0.41-2.48%
Market Closed Sep 6 15:00 CST
3.75BMarket Cap136.61P/E (TTM)
16.60High16.10Low12.22KlotVolume16.50Open16.53Pre Close19.83MTurnover0.78%Turnover Ratio50.06P/E (Static)232.52MShares25.3852wk High0.64P/B2.52BFloat Cap14.6952wk Low18.18Limit Up156.09MShs Float59.65Historical High14.88Limit Down3.03%Amplitude1.36Historical Low0.12Dividend TTM16.23Avg Price7.87KlotAsk0.74%Div YieldTTM100Lot Size4.28KlotBid
Wuhan Easy Diagnosis Biomedicine Key Stats
All
YOY
| (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | -55.05%403.61M | -42.36%229.6M | -79.79%1.8B | -73.83%1.45B | -74.78%898.02M | -73.17%398.36M | 269.05%8.89B | 250.46%5.53B | 285.68%3.56B | 150.89%1.48B |
| Refunds of taxes and levies | 6,913.89%463.81K | --257.98K | 37.54%2.64M | -28.44%1.01M | -98.62%6.61K | ---- | 1,596.66%1.92M | 1,142.65%1.41M | --480.29K | --11.27K |
| Net deposit increase | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net increase in borrowings from central bank | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net increase in placements from other financial institutions | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash received from interests, fees and commissions | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net increase in repurchase business capital | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Premiums received from original insurance contracts | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net cash received from reinsurance business | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net increase in deposits from policyholders | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net increase in funds disbursed | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net cash received from trading securities | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash received relating to other operating activities | 228.70%83.86M | 419.16%64.46M | -49.80%98.03M | -44.21%19.65M | -7.46%25.51M | -32.30%12.42M | 326.06%195.3M | -62.64%35.21M | 123.71%27.57M | 276.59%18.34M |
| Cash inflows from operating activities | -47.17%487.94M | -28.35%294.32M | -79.12%1.9B | -73.63%1.47B | -74.27%923.53M | -72.67%410.77M | 270.18%9.09B | 232.88%5.57B | 283.59%3.59B | 151.92%1.5B |
| Goods services cash paid | -32.92%265.08M | -42.45%107.86M | -77.50%641.87M | -74.22%545.94M | -74.25%395.19M | -77.63%187.41M | 265.82%2.85B | 357.71%2.12B | 429.67%1.53B | 306.83%837.91M |
| Staff behalf paid | -38.82%139.28M | -30.85%87.12M | -29.77%353.97M | -9.78%284.98M | 1.56%227.65M | 42.25%125.98M | 173.03%503.99M | 136.85%315.88M | 170.82%224.15M | 85.38%88.56M |
| All taxes paid | -97.62%7.93M | -98.03%6.27M | -78.36%271.54M | -71.73%266.45M | -42.85%332.8M | 62.35%317.52M | 470.31%1.25B | 382.32%942.51M | 272.77%582.35M | 205.28%195.57M |
| Net loan and advance increase | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net deposit in central bank and institutions | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net lend capital | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash paid for fees and commissions | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash paid for indemnity of original insurance contract | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Policy dividend cash paid | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash paid relating to other operating activities | 28.22%233.6M | -60.85%47.38M | -48.95%238.54M | -30.25%210.96M | -7.53%182.18M | 32.68%121.04M | 223.25%467.26M | 225.49%302.45M | 206.63%197.02M | 253.80%91.23M |
| Cash outflows from operating activities | -43.23%645.89M | -66.94%248.63M | -70.35%1.51B | -64.44%1.31B | -55.17%1.14B | -38.02%751.96M | 282.15%5.08B | 315.95%3.68B | 328.03%2.54B | 253.12%1.21B |
| Net cash flows from operating activities | 26.29%-157.96M | 113.39%45.69M | -90.22%392.5M | -91.53%160.2M | -120.39%-214.29M | -217.75%-341.18M | 256.06%4.01B | 139.73%1.89B | 206.70%1.05B | 14.50%289.75M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | -89.72%302M | -99.74%5M | -9.89%3.92B | 68.17%2.99B | 267.30%2.94B | 290.00%1.95B | 168.52%4.35B | 54.78%1.78B | -8.05%800M | 61.29%500M |
| Cash received from returns on investments | -96.95%824.71K | -97.39%423.9K | -6.63%34.71M | 79.06%28.66M | 246.96%27.01M | 267.01%16.23M | 476.54%37.18M | 248.90%16.01M | 154.87%7.79M | 302.78%4.42M |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | 471.66%427.08K | --67.38K | --146.36K | --165.59K | --74.71K | --0 | ---- | ---- | ---- | --3.9K |
| Net cash received from disposal of subsidiaries and other business units | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Cash received relating to other investing activities | --0 | ---- | ---- | ---- | ---- | --0 | ---- | --239.7K | ---- | ---- |
| Cash inflows from investing activities | -89.77%303.25M | -99.72%5.49M | -9.86%3.95B | 68.25%3.02B | 267.11%2.97B | 289.80%1.97B | 169.74%4.39B | 55.57%1.8B | -7.48%807.79M | 62.14%504.43M |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | 138.78%114.48M | 182.18%61.44M | -64.91%109.97M | -65.17%82.31M | -73.14%47.94M | -66.89%21.77M | 202.59%313.38M | 291.14%236.31M | 367.60%178.52M | 225.38%65.75M |
| Cash paid to acquire investments | -92.46%190M | ---- | -17.41%5.21B | -5.01%2.68B | 113.17%2.52B | 96.35%981.75M | 185.69%6.31B | 89.03%2.82B | 40.66%1.18B | 8.70%500M |
| Net cash paid to acquire subsidiaries and other business units | 748.57%14.85M | --4.65M | ---- | --1.75M | --1.75M | ---- | ---- | ---- | ---- | ---- |
| Impawned loan net increase | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash paid relating to other investing activities | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --70M | ---- |
| Cash outflows from investing activities | -87.57%319.33M | -93.41%66.09M | -19.66%5.32B | -9.61%2.76B | 79.60%2.57B | 77.38%1B | 186.45%6.62B | 96.90%3.05B | 62.84%1.43B | 17.81%565.75M |
| Net cash flows from investing activities | -104.05%-16.08M | -106.29%-60.6M | 38.90%-1.37B | 120.90%262.66M | 163.81%397.05M | 1,669.92%962.71M | -226.10%-2.23B | -217.46%-1.26B | -12,048.77%-622.28M | 63.74%-61.32M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | --0 | ---- | ---- | ---- | -101.52%-504.82K | ---- | -92.00%38.6M | 753.24%35.12M | --33.15M | --24.5M |
| -Including: Cash received from capital contributions by minority shareholders of subsidiaries | --0 | ---- | ---- | ---- | ---- | ---- | ---- | --35.12M | ---- | --24.5M |
| Cash from borrowing | --0 | ---- | -82.81%23.61M | -15.25%19.85M | -15.25%19.85M | -15.25%19.85M | 357.95%137.39M | -21.94%23.42M | --23.42M | --23.42M |
| Cash received relating to other financing activities | --0 | ---- | --34.83M | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Cash inflows from financing activities | --0 | --0 | -66.79%58.44M | -66.10%19.85M | -65.81%19.34M | -58.58%19.85M | -65.68%175.99M | 71.59%58.54M | --56.57M | --47.92M |
| Borrowing repayment | --22.16M | --13.64M | 134.00%125M | 71.34%51.46M | ---- | ---- | -62.25%53.42M | -78.84%30.04M | -78.77%30.04M | ---- |
| Dividend interest payment | -92.93%40.88M | -48.75%104.95K | 5.78%582.48M | 5.22%578.16M | 83.59%577.94M | 347.34%204.78K | 94.30%550.64M | 93.71%549.45M | 35,505.63%314.79M | -59.84%45.78K |
| -Including:Cash payments for dividends or profit to minority shareholders | --13.2M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash payments relating to other financing activities | -95.06%102.21K | --780.73K | 344.98%21.02M | -58.98%3.37M | --2.07M | ---- | -14.83%4.72M | 215.63%8.2M | ---- | 1,701.54%203.43K |
| Cash outflows from financing activities | -89.11%63.14M | 6,993.18%14.53M | 19.67%728.5M | 7.71%632.99M | 68.20%580.01M | -17.83%204.78K | 41.43%608.78M | 37.26%587.69M | 137.84%344.83M | -99.70%249.21K |
| Net cash flows from financing activities | 88.74%-63.14M | -173.95%-14.53M | -54.82%-670.06M | -15.87%-613.14M | -94.50%-560.67M | -58.80%19.64M | -626.05%-432.79M | -34.28%-529.15M | -98.82%-288.26M | 157.97%47.67M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | -103.44%-63.35K | -27.63%-376.41K | -93.52%1.26M | -93.65%1.2M | -87.70%1.84M | 70.62%-294.92K | 709.21%19.47M | 2,747.79%18.94M | 1,364.49%14.97M | -12,175.00%-1M |
| Net increase in cash and cash equivalents | 36.92%-237.23M | -104.65%-29.81M | -220.22%-1.64B | -252.85%-189.08M | -341.77%-376.07M | 132.97%640.88M | 162.08%1.37B | 6,322.15%123.71M | -18.74%155.55M | 15,975.32%275.09M |
| Add:Begin period cash and cash equivalents | -64.23%914.04M | -64.23%914.04M | 114.73%2.56B | 114.73%2.56B | 114.73%2.56B | 114.73%2.56B | 77.86%1.19B | 77.86%1.19B | 77.86%1.19B | 77.88%1.19B |
| End period cash equivalent | -68.95%676.81M | -72.34%884.23M | -64.23%914.04M | 80.12%2.37B | 61.96%2.18B | 118.16%3.2B | 114.73%2.56B | 96.94%1.31B | 56.37%1.35B | 118.44%1.47B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- |
| Auditor | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
% Chg